arrow
L

LaQuisa Hill

Baylor College of Medicine
H指数:15
被引数:786

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

在费城染色体阳性急性淋巴细胞白血病中使用Brexucabtagene Autoleucel治疗后,TKI维持疗法可改善疗效

2026-06-290
OA
Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial

供者特异性移植结局来自BMTCTN 1702:一项多中心前瞻性生物分配试验

2026-06-090
OAAI
Consensus Recommendations for CAR T Cell Administration in Adult Acute Lymphoblastic Leukemia: A Modified Delphi Study

成人急性淋巴细胞白血病CAR T细胞输注的共识建议:一项改良德尔菲研究

Blood
IF23.1
2026-05-220
PRE
Blinatumomab Non-response Correlates with Poor Survival After Brexucabtagene Autoleucel in B-cell ALL

Blinatumomab无应答与Brexucabtagene autoleucel治疗后B细胞急性淋巴细胞白血病患者预后不良相关

Blood
IF23.1
2026-02-090
PRE
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial

供者检索与选择策略以促进不同供者检索预后组间可比的移植率:BMT CTN 1702试验报告

2026-01-150
PRE
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial

基于供者搜索预后对同种异体细胞移植的准入:BMT CTN 1702试验

2025-11-080
PRE
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

国际共识指南:关于AML CAR T细胞临床研究的实施与报告

2025-08-210
OAAI
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma

新型合并症指数与大型B细胞淋巴瘤嵌合抗原受体T细胞治疗后生存期的关联

2025-08-180
OAAI
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Brexucabtagene autoleucel在伴有CNS受累的复发/难治性急性淋巴细胞白血病患者中的疗效

2025-05-090
OAAI
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

真实世界(RW)结局:Brexucabtagene autoleucel(Brexu-Cel)治疗具有高风险特征及既往治疗史患者的复发或难治性B细胞急性淋巴细胞白血病(R/R B-ALL)结局;来自CIBMTR®登记数据的更新证据

BLOOD
IF23.1
2024-11-051
PRE
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Brexucabtagene autoleucel治疗60岁及以上患者复发/难治性B细胞急性淋巴细胞白血病的有效性与安全性

BLOOD
IF23.1
2024-11-051
PRE
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity

嵌合抗原受体诱导的抗原丢失可保护CD5.CART细胞免受自杀性杀伤,而不会损害靶向细胞毒性

2024-07-012
OAAI
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies

CD7-unedited CD7 CAR T细胞治疗T细胞恶性肿瘤的可行性和临床前疗效

2023-01-0135
OAAI